Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
29.69
-0.29 (-0.97%)
At close: Feb 27, 2026, 4:00 PM EST
29.75
+0.06 (0.20%)
After-hours: Feb 27, 2026, 7:43 PM EST
Alumis Employees
As of December 31, 2024, Alumis had 170 total employees, including 221 full-time and 2 part-time employees. The number of employees increased by 61 or 55.96% compared to the previous year.
Employees
170
Change (1Y)
61
Growth (1Y)
55.96%
Revenue / Employee
$99,197
Profits / Employee
-$1,099,341
Market Cap
3.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 170 | 61 | 55.96% |
| Dec 31, 2023 | 109 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| Corcept Therapeutics | 730 |
| ADMA Biologics | 685 |
| ACADIA Pharmaceuticals | 654 |
| Arcutis Biotherapeutics | 342 |
| Xenon Pharmaceuticals | 327 |
| Centessa Pharmaceuticals | 114 |
| NewAmsterdam Pharma Company | 100 |
ALMS News
- 23 days ago - Alumis to Participate in Upcoming February Investor Conferences - GlobeNewsWire
- 7 weeks ago - Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 7 weeks ago - Alumis Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise - Seeking Alpha
- 7 weeks ago - Alumis Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars - Benzinga
- 7 weeks ago - Alumis skin disease drug meets main goal of two late-stage trials - Reuters
- 7 weeks ago - Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program - GlobeNewsWire